Chen J, Danping L, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. J Zhejiang Univ (Med Sci). 2019;49:215-219.
Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv.2020.03.22.20040758.
European League Against Rheumatism. EULAR COVID-19 Database. Updated July 6, 2020. Accessed July 17, 2020. https://www.eular.org/myUploadData/files/eular_covid19_database_infographic_as_of_6_july.pdf
Fisk M, Livingstone A, Pit SW. Telehealth in the context of COVID-19: changing perspectives in Australia, the United Kingdom, and the United States. J Med Internet Res. 2020;22(6):e19264.
Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020. doi:10.1016/j.ijantimicag.2020.105949. [Epub ahead of print]
Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79:859-866.
Landewé RB, Machado PM, Kroon F, et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020;79:851-858.
Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. Preprint. medRxiv. 2020;2020.04.16.20065920.
Mahévas M, Tran VT, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with COVID-19 pneumonia who require oxygen: observational comparative study using routine care data [published correction appears in BMJ.2020;369:m2328]. BMJ. 2020;369:m1844.
Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: version 1 [published online ahead of print, 2020 Apr 29]. Arthritis Rheumatol. 2020;10.1002/art.41301. doi:10.1002/art.41301
Sanchez-Piedra C, Diaz-Torne C, Manero J, et al. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Ann Rheum Dis. 2020;79:988-990.
Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;369:m1849.
Horby P, Lim WS, Emberson J, et al. Effect of dexamethasone in hospitalized patients with COVID-19: preliminary report. medRxiv 2020.06.22.20137273 https://www.medrxiv.org/content/10.1101/2020.06.22.20137273v1
World Health Organization. "Solidarity" clinical trial for COVID-19 treatments. Updated July 6, 2020. Accessed July 6,2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-clinical-trial-for-covid-19-treatments.

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Ronald van Vollenhoven, MD, PhD

Professor of Rheumatology
Amsterdam University Medical Centers
Amsterdam, the Netherlands

Disclosures

Disclosure: Ronald van Vollenhoven, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; AstraZeneca Pharmaceuticals LP; Biogen; Biotest; Celgene Corporation; Glapagos; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Pfizer Inc.; SERVIER; UCB Pharma, Inc.
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Galapagos; Janssen Pharmaceuticals; Pfizer Inc.; UCB Pharma, Inc.
Received grants for clinical research from: Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; UCB Pharma, Inc.

Marta Mosca, MD, PhD

Associate Professor of Rheumatology
University of Pisa
Pisa, Italy

Disclosures

Disclosure: Marta Mosca, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eli Lilly and Company; UCB Pharma, Inc.
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Bristol-Myers Squibb Company; Sanofi
Received grants for clinical research from: Pfizer Inc.

Editor

Shanthi Voorn, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Shanthi Voorn, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CPD

Where Are We Now in Managing Patients With SLE During the COVID-19 Pandemic?

Authors: Ronald van Vollenhoven, MD, PhD; Marta Mosca, MD, PhD
CPD Released: 7/29/2020
THIS ACTIVITY HAS EXPIRED
Valid for credit through: 7/29/2021

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US primary care physicians, rheumatologists, and nephrologists.

The goal of this activity is to increase knowledge on the management of patients with systemic lupus erythematosus (SLE) during the COVID-19 era.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Latest information on COVID-19 and its impact on patients with SLE
- Rheumatological care for patients with SLE in a COVID era

Disclosures

Faculty

Ronald van Vollenhoven, MD, PhD

Professor of Rheumatology
Amsterdam University Medical Centers
Amsterdam, the Netherlands

Disclosures

Disclosure: Ronald van Vollenhoven, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; AstraZeneca Pharmaceuticals LP; Biogen; Biotest; Celgene Corporation; Glapagos; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Pfizer Inc.; SERVIER; UCB Pharma, Inc.
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Galapagos; Janssen Pharmaceuticals; Pfizer Inc.; UCB Pharma, Inc.
Received grants for clinical research from: Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline; UCB Pharma, Inc.

Marta Mosca, MD, PhD

Associate Professor of Rheumatology
University of Pisa
Pisa, Italy

Disclosures

Disclosure: Marta Mosca, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Eli Lilly and Company; UCB Pharma, Inc.
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Bristol-Myers Squibb Company; Sanofi
Received grants for clinical research from: Pfizer Inc.

Editor

Shanthi Voorn, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Shanthi Voorn, PhD, has disclosed no relevant financial relationships.

Content Reviewer

Esther Nyarko, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.25 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

Where Are We Now in Managing Patients With SLE During the COVID-19 Pandemic?

Authors: Ronald van Vollenhoven, MD, PhD; Marta Mosca, MD, PhDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED

CPD Released: 7/29/2020

Valid for credit through: 7/29/2021

processing....

CPD Information Download Slides

Activity Transcript

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

References

Faculty and Disclosures

Faculty

Ronald van Vollenhoven, MD, PhD

Marta Mosca, MD, PhD

Editor

Shanthi Voorn, PhD

Content Reviewer

Esther Nyarko, PharmD

CPD

Where Are We Now in Managing Patients With SLE During the COVID-19 Pandemic?

Target Audience and Goal Statement

Disclosures

Faculty

Ronald van Vollenhoven, MD, PhD

Marta Mosca, MD, PhD

Editor

Shanthi Voorn, PhD

Content Reviewer

Esther Nyarko, PharmD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Where Are We Now in Managing Patients With SLE During the COVID-19 Pandemic?